On April 24, 2014 AstraZeneca reported that AZD9291 has been granted Breakthrough Therapy designation by the US FDA for the treatment of patients with metastatic, EGFR T790M mutation-positive, non-small cell lung cancer (NSCLC) whose NSCLC has progressed during treatment with an FDA-approved, EGFR tyrosine kinase inhibitor (Press release AstraZeneca, APR 24, 2014, View Source;first-quarter-results-2014 [SID:1234500464]).